No Data
No Data
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare
Jim Cramer on Repligen Corporation (RGEN): 'I'm Not Quite Ready to Stick My Neck Out on This One'
A Quick Look at Today's Ratings for Repligen(RGEN.US), With a Forecast Between $189 to $207
Repligen's Strong Market Position and Growth Potential Justify Buy Rating Amid Minimal Tariff Exposure
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty
Repligen Is Maintained at Outperform by RBC Capital